Genomic Alterations Associated with Estrogen Receptor Pathway Activity in Metastatic Breast Cancer Have a Differential Impact on Downstream ER Signaling.
Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 6 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
15 authors at 8 institutions in 1 country.
Lindsay AngusDepartment of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Cancer, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands.ORCID 0000-0002-7928-1102
Marcel SmidDepartment of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Cancer, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands.ORCID 0000-0003-0605-1901
Saskia M WiltingDepartment of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Cancer, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands.ORCID 0000-0002-2838-841X
Manouk K BosDepartment of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Cancer, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands.ORCID 0000-0002-2984-7542
Neeltje SteeghsDepartment of Medical Oncology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.ORCID 0000-0003-2989-2279
Inge R H M KoningsDepartment of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands.
Vivianne C G Tjan-HeijnenCenter for Personalized Cancer Treatment, 6500 HB Nijmegen, The Netherlands.
Johanna M G H van RielDepartment of Internal Medicine, Elisabeth-TweeSteden Hospital, 5022 GC Tilburg, The Netherlands.
Agnes J van de WouwDepartment of Medical Oncology, VieCuri Medical Center, 5912 BL Venlo, The Netherlands.ORCID 0000-0002-2229-3970
Cpct ConsortiumCenter for Personalized Cancer Treatment, 6500 HB Nijmegen, The Netherlands.
Edwin CuppenCenter for Molecular Medicine and Oncode Institute, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands.ORCID 0000-0002-0400-9542
Martijn P LolkemaDepartment of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Cancer, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands.ORCID 0000-0003-0466-2928
Agnes JagerDepartment of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Cancer, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands.
Stefan SleijferDepartment of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Cancer, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands.
John W M MartensDepartment of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Cancer, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands.ORCID 0000-0002-3428-3366
Erasmus MC Cancer Institute · NLCenter for Personalized Cancer Treatment · NLAmsterdam University Medical Centers · NLElisabeth-TweeSteden Ziekenhuis · NLMaastricht University · NLThe Netherlands Cancer Institute · NLUniversity Medical Center Utrecht · NLVieCuri Medisch Centrum · NL
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Mutations in the estrogen receptor gene (
Indexed as
breast cancerendocrine resistanceRNA sequencingwhole genome sequencing
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.